Chesapeake Capital Corp IL Acquires New Position in Merck & Co., Inc. $MRK

Chesapeake Capital Corp IL acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 8,710 shares of the company’s stock, valued at approximately $917,000.

Other large investors also recently bought and sold shares of the company. United Financial Planning Group LLC purchased a new stake in Merck & Co., Inc. during the 3rd quarter valued at about $31,000. Wealth Watch Advisors INC purchased a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $34,000. Dunhill Financial LLC grew its stake in shares of Merck & Co., Inc. by 83.0% in the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock valued at $35,000 after buying an additional 190 shares during the period. Silicon Valley Capital Partners grew its stake in shares of Merck & Co., Inc. by 160.5% in the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock valued at $35,000 after buying an additional 260 shares during the period. Finally, Valued Wealth Advisors LLC grew its stake in shares of Merck & Co., Inc. by 26.9% in the 4th quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock valued at $47,000 after buying an additional 94 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a landmark Science paper on a new large-scale biocatalytic synthesis method for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The work supports manufacturing scalability for a potential future cardiovascular drug and underscores progress in Merck’s pipeline. Article Title
• Positive Sentiment: Merck also became the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies under a five-year agreement, strengthening its BioReliance services business and adding a recurring commercialization-related revenue stream. Article Title
• Neutral Sentiment: Analyst commentary highlighted Merck as a well-prepared dividend stock despite its upcoming patent cliff, suggesting the market is still weighing long-term earnings durability rather than reacting to a single catalyst. Article Title
• Negative Sentiment: Merck is heading toward a July 27 trial over Gardasil safety claims after the vaccine reached an $8.9 billion sales peak. The litigation risk could weigh on sentiment around one of Merck’s key growth franchises, even though the company continues to defend the product’s safety record. Article Title

Insiders Place Their Bets

In related news, CMO Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The shares were sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the sale, the chief marketing officer directly owned 70,615 shares in the company, valued at $8,361,522.15. This trade represents a 12.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the sale, the executive vice president owned 68,916 shares in the company, valued at $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.17% of the stock is currently owned by company insiders.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $111.26 on Friday. The firm has a market cap of $274.78 billion, a PE ratio of 31.34, a price-to-earnings-growth ratio of 2.53 and a beta of 0.18. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The company’s 50 day moving average is $117.07 and its two-hundred day moving average is $108.31.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Cantor Fitzgerald increased their price target on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. TD Cowen increased their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. Wells Fargo & Company dropped their price target on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Weiss Ratings reissued a “hold (c+)” rating on shares of Merck & Co., Inc. in a research note on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research note on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average target price of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.